Nasdaq:US$15.97 (-0.33) | HKEX:HK$25.65 (+0.20) | AIM:£2.41 (+0.1)
News & Presentations
Previous Article   |   Next Article
Presentations, Scientific Publications | 16 Oct 2010

ISSX 2011: Preclinical assessment of the absorption, distribution, metabolism and excretion of HMPL-013 (fruquintinib), a novel potent and specific VEGFR inhibitor